UM researchers partner with Taumedis to develop breakthrough cancer imaging technology

University of Manitoba (UM) researchers and Taumedis Inc., a Winnipeg-based medical technology company are announcing a research partnership to investigate patent-pending imaging technology that could address a longstanding challenge; early breast cancer detection.  

According to the Canadian Cancer Society, breast cancer is the most commonly diagnosed cancer in women (excluding non-melanoma skin cancers), and 1 in 8 women will be diagnosed in North America.

Mammography remains the standard for screening and diagnostic protocols, but gaps in access, capacity, and performance—particularly in dense breast tissue—continue to impact timely diagnosis.  Taumedis and UM are developing a novel dual-mode imaging technology that distinguishes between different tissue types and properties. This technology could complement existing screening methods.

“We are proud to partner with the University of Manitoba to advance a new generation of breast imaging solutions,” says Henry Floreal, Co-Founder and CEO of Taumedis. “By combining Taumedis’ innovation in medical imaging with the University’s research excellence, we aim to advance imaging technologies and support future improvements in clinical assessment, with the goal of ultimately improving patient outcomes.”

Taumedis is currently working with Professor Joe LoVetri's team in the Electromagnetic Imaging Laboratory at the UM’s Price Faculty of Engineering.

“This collaboration with Taumedis will enable the technological advancements required to bring this unique, dual-mode imaging technology to the point of clinical trials. It is a partnership that will fuel biomedical imaging innovation in Manitoba and stands as a testament to the global research excellence established in our lab which also includes significant contributions of numerous students, researchers, and professors over the past 20 years."

As Taumedis and engineering researchers work to refine the technical design, Dr. Cameron Kaye, Co-Principal Investigator and Assistant Professor in the Department of Radiology, Max Rady College of Medicine will work with Taumedis towards a First-in-Human (FIH) study. 

“There is a clear need to advance breast imaging technologies to address existing shortfalls in breast cancer detection, particularly in patients with dense breast tissue.” says Dr. Cameron Kaye. “This research partnership allows us to rigorously evaluate a novel, non-ionizing imaging approach that that may complement current standards of care, subject to further clinical assessment.”

The First-in-Human (FIH) study is subject to regulatory and ethics approvals but planned for later in 2026.

Beyond advancing early-stage research, this partnership supports Manitoba’s innovation economy, reinforces local capabilities in medical technology development, builds high-value technical expertise, and contributes to the province’s broader strategy to grow a competitive, knowledge-based economy.

The technology is being developed with the long-term goal of potential clinical and commercial application, subject to further research and regulatory approval.

About Taumedis 
Taumedis is an early-stage medical imaging company focused on developing advanced solutions to improve disease detection and clinical decision-making. By combining innovative imaging technologies with a deep understanding of clinical workflows, Taumedis aims to enhance diagnostic accuracy, increase efficiency, and expand access to high-quality care. For more information please see Taumedis.com.  

For Interviews, please contact:

UM Media Relations  
mediarelations@umanitoba.ca  

Taumedis Media Contact: 
Jay Mitchosky, VP, Sales & Marketing 
jmitchosky@taumedis.com